Partnerships and Licensing

Current Partners:

Vybion has a Strategic Partnership with Meridian Life Sciences to promote and manage the application of ProCode to the diagnostic and biomarker market.

Vybion is a Partner in the Viral Hemorrhagic Fever Consortium providing ProCode and recombinant protein development . The Consortium partners include Tulane Medical School, Corgenix, Scripps Institute, Harvard, UCSD, and others. With a clinic in Sierra Leone and a presence in Nigeria, the Consortium has deployed the first ever Lassa Fever ELISA and LFI Diagnostic. Lassa Fever is a potentially fatal Hemorrhagic illness of the Arenaviridae family of viruses.

Opportunities:

Vybion technology available for partnerships or out-licensing include:

• ProCode for antibody like therapeutic drugs and diagnostics
• N-terminal pegylation to fine tune pharmacokinetics
• AmPlex, a multiplexing immunodiagnostic platform with up to 10,000 fold amplification capabilities